References

Cure Arthritis Naturally

Cure Arthritis Naturally

Get Instant Access

American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39:723-731 Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH (2004) Factors associated with chloroquine-

induced retinopathy in rheumatic diseases. Lupus 13:119-124 Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75-83 Asch PH, Caussade P, Marquart-Elbaz C, Boehm N, Grosshans E (1997) Chloroquine-induced achro-

motrichia. An ultrastructural study. Ann Dermatol Venereol 124:552-556 Avina-Zubieta JA, Galindo-Rodriguez S, Newman S, Suarez-Almazor ME, Russell AS (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57: 582-587 Baguet JP, Tremel F, Fabre M (1999) Chloroquine cardiomyopathy with conduction disorders. Heart 81:221-223

Barthel HR, Meier LG, Wallace DJ (1996) Antimalariamittel bei rheumatischen Erkrankungen. Dtsch med Wschr 121:1576-1582 Bauer F (1981) Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential. A review. J Am Acad Dermatol 4:239-248 Becerra-Cunat JL, Coll-Canti J, Gelpi-Mantius E, Ferrer-Avelli X, Lozano-Sanchez M, Millan-Torne M, Ojan-guren I, Ariza A, Olive A (2003) Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with areflexia that simulates a polyradiculoneuropathy. Two case reports. Rev Neurol 36:523-526 Benagiano G (2001) Non-surgical female sterilization with quinacrine: an update. Contraception 63:239-245

Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703-2706 Boelaert JR, Piette J, Sperber K (2001) The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20:137-140

Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780-785 Borden MB, Parke AL (2001) Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 24:1055-1063

Callaway JL (1979) Late sequelae of quinacrine dermatitis, a new premalignant entity. J Am Acad Dermatol 1:456-457

Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New Engl J Med 324:150-154 Canadian rheumatology association (2000) Canadian Consensus Conference on hydroxychloroquine.

J Rheumatol 27:2919-2921 Carmichael SJ, Charles B, Tett SE (2003) Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 25:671-681 Chung HS, Hann SK (1997) Lupus panniculitis treated by a combination therapy of hydroxychloro-

quine and quinacrine. J Dermatol 24:569-572 Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, Wall B, Wallace DJ, Bell CL, Sleckman J (1997) Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 24:1896-1902 Clemessy JL, Taboulet P, Hoffmann JF, Hantson P, Barriot P, Bismuth C, Baud J (1996) Treatment of acute chloroquine poisoning: a 5-year experience. Critical Care Med 24:1189-1195 Costedoat-Chalumeau N,Amoura Z, Duhaut P, Huong du LT, Sebbough D, Wechsler B,Vauthier D, Den-joy I, Lupoglazoff JM, Piette JC (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a controll group. Arthritis Rheum 48:3207-3211 D'Cruz D (2001) Antimalarial therapy: a panacea for mild lupus? Lupus 10:148-151 Dereure O, Guilhou JJ (2002) Eosinophilic-like erythema: a clinical subset of Well's eosinophilic cel-

lulitis responding to antimalarial drugs? Ann Dermatol Venereol 129:720-723 Dubois EL (1976) Lupus erythematosus, 2nd edn. University of Southern California Press, Los Angeles, pp 548, 588

Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokin 31:257-274 Dutz JP, Ho VC (1998) Immunosuppressive agents in dermatology: an update. Dermatol Clin 16:235-251 Easterbrook M (1985) The sensitivity of Amsler grid testing in early chloroquine retinopathy. Trans

Opthalmol Soc UK 104:204-207 Engel GL, Romano J, Ferris Eb (1947) Effect of quinacrine on the central nervous system. Arch Neurol 58:337-350

Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41:924-929 Espinola RG, Pierangeli SS, Ghara AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518-522 Feldmann R, Salomon D, Saurat JH (1994) The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 189:425-427

Ferrante A, Rowan-Kelly B, Seow WK, Thong YH (1986) Depression of human polymorphonuclear leucocyte function by anti-malarial drugs. Immunology 85:125-130 Fox RI, Dixon R, Guarrassi V,Krubel S (1996) Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 (Suppl 6):S31-S36 Fries JF, Williams CA, Ramey DR, Block DA (1993) The relative toxicity of the disease-modifying antirheumatic drugs. Arthritis Rheum 36:297-306 Humphreys F, Mrks JM (1988) Mepacrine and pregnancy. Br J Dermatol 118:452 Jancinova V, Nosal R, Drabikova K, Danihelovaa E (2001) Cooperation of chloroquine and blood platelets in inhibition of polymorphonuclear leukocyte chemiluminescence. Biochem Pharmacol 62:1629-636

Jeong JY, Choi JW, Jeon KI, Jue DM (2002) Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 105:83-91 Jessop S, Whitelaw D, Jordaan F (2004) Drugs for discoid lupus erythematosus (Cochrane Review). In: The Cochrane Library, Issue 2, Chichester, UK, Y. Wiley & Sons Ltd.

Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983-987 Johansen PB, Gran JT (1998) Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 16:472-474

Jones SK (1999) Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 140:3-7

Jordan P, Brookes JG, Nikolic G, Le Couteur DG (1999) Hydroxychloroquine overdose: toxicokinetics and management. J Toxicol Clin Toxicol 37:861-864 Khoury H, Trinkaus K,Zhang MJ,Adkins D, Brown R,Vij R, Goodnough LT, Ma MK,McLeod HL, Shenoy S, Horowitz M, Dispersio JF (2003) Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant 9:714-721 Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358:813-814

Krishna S, White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokin 30:263-299 Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus - a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Derma-tol 136:1033-1041

Laaksonen AL, Koskiahde V, Juva K (1974) Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 3:103-109 Leigh JM, Kennedy CTC, Ramsey JD, Henderson WJ (1979) Mepacrine pigmentation in systemic lupus erythematosus. Br J Dermatol 101:147-153 Levy GD, Munz SJ, Paschal J (1997) Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicentre outpatient practice. Arthritis Rheum 40:1482-1486 Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, Albuquerque EM, Jesus NR (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:401-404

Liu ST, Wang CR, Yin GD, Liu MF, Lee GL, Chen MY, Chuang CY, Chen CY (2001) Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 19:29-35 Loudon JR (1988) Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Amer J Med 85(Suppl 4a):57-61 Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antima-

larials. Am J Med 75(Suppl):40-45 Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R (1994) Fulminant hepatic failure secondary to hydroxychloroquine. Gut 35:569-570 Maksymowych W, Russell AS (1987) Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 16:206-221

Malcangi G, Fraticelli P, Palmieri C, Cappelli M, Danieli MG (2000) Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. Rheumatol Int 20:31-33 Marquardt K, Albertson TE (2001) Treatment of hydroxychloroquine overdose. Am J Emerg Med 19:420-424

Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reap-paraisal. Ophthalmology 110:1321-1326 McDuffie FC (1965) Bone marrow depression after drug therapy in patients with systemic lupus ery-

thematosus. Ann Rheum Dis 24:289-292 Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E (1996) Controlled trial with chloroquine diphos-

phate in systemic lupus erythematosus. Lupus 5:237-241 Metayer I, Balguerie X, Courville P, Lauret P, Joly P (2001) Photodermatosis induced by hydroxychloroquine: 4 cases. Ann Dermatol Venereol 128:729-731 Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ (1987) Plasma hydroxy-

chloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 30:567-571 Minzi OM, Rais M, Svensson JO, Gustafsson LL, Ericsson O (2003) High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 783:473-480

Mitja K, Izidor K, Music E (2000) Chloroquine-induced drug hypersensitivity alveolitis. Pneumologie 54:395-397

Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, Amit-Vazina M (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11:356-361 Morgan KW, Callen JP (2001) Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 28:2129-2132 Murphy M, Carmichael AJ (2001) Fatal toxic epidermal necrolysis associated with hydroxychloro-

quine. Clin Exp Dermatol 26:457-458 Nguyen K, Washenik K, Shupack J (2002) Necrobiosis lipoidica diabeticorum treated with chloroquine.

J Am Acad Dermatol 45:S34-36 [No authors listed] (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the

HERA study. Amer J Med 98:156-168 Nord JE, Shah PK, Rinaldi RZ, Weisman MH (2004) Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 33:336-351

Ochsendorf FR, Runne U (1991) Chloroquin und Hydroxychloroquin: Nebenwirkungsprofil wichtiger

Therapeutika. Hautarzt 42:140-146 Ochsendorf FR, Runne U (1991) Subakute Chloroquin-Überdosierung: Schwindel, körperliche Schwäche, bullöse Lichtreaktion, Sehstörungen und generalisierte Weißfärbung der Haare. Dtsch med Wschr 116:1513-1516 Ochsendorf FR, Runne U, Goerz G, Zrenner E (1993) Chloroquin-Retinopathie: durch individuelle

Tagesdosis vermeidbar. Dtsch Med Wochenschr 118:1895-1898 Ochsendorf FR, Runne U (1997) Therapie des systemischen Lupus erythematodes. Dtsch Med Wochenschr 122:877

O'Dell JC, Haire C, Erikson N, Drymalski W, Palmer W, Eckhoff J, Garwood V, Maloley P, Klassen L, Wees S, Klein H, Moore G (1996) Treatment of rheumatoid arthritis with methotrexate alone, sul-fasalazine and hydroxychloroquine or a combination of all three medications. New Engl J Med 344:1287-1291

O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164-1170 Onigbogi O, Ajayi AA, Ukponmwan OE (2000) Mechanisms of chloroquine-induced body-scratching behavior in rats: evidence of involvement of endogenous opioid peptides. Pharmacol Biochem Behav 65:333-337

Onyeji CO, Ogunbona FA (2001) Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. Eur J Pharm Sci 13:195-201 Orteu CH, Buchanan JA, Hutchison I, Leigh IM, Bull RH (2001) Systemic lupus erythematosus presenting with oral mucosal lesions: easily missed? Br J Dermatol 144:1219-1223 Ostensen M, Ramsey-Goldman R (1998) Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 19:389-410 Parke AL,West B (1996) Hydroxychloroquine in pregnant patients with SLE.J Rheumatol 23:1715-1718 Petri M (1996) Hydroxychloroquine use in the Baltimore lupus cohort. Effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16-S22 Pinckers A, Broekhuyse RM (1983) The EOG in rheumatoid arthritis. Acta Ophthalmol 61:831-837 Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN (1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26:325-330

Reeves GE,Boyle MJ,Bonfield J, Dobson P, Loewenthal M (2004) Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 34:182-186 Reuss-Borst M, Berner B, Wulf G, Muller GA (1999) Complete heart block as a rare complication of treatment with chloroquine. J Rheumatol 26:1394-1395 Rigaudiere F, Ingster-Moati I, Hache JC, Leid J,Verdet R, Haymann P, Rigolet MH, Zanlonghi X, Defoort S, Le Gargasson JF (2004) Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophthalmol 27:191-199

Ruiz-Irastorza G, Khamashta MA, Hughes GR (2000) Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 9:1581-1593 Runne U, Ochsendorf FR, Schmid K, Raudonat HW (1992) Sequential concentration of chloroquine in human hair correlates with ingested dose and duration of therapy. Acta Derm Venereol (Stockh) 72:355-357

Savarino A, Gennero L, Sperber K, Boelaert JR (2001) The anti-HIV-1 activity of chloroquine. J Clin Virol 20:131-135

Scherbel AL, Mackenzie AH, Nousek JE, Adtjian M (1965) Ocular Lesions in Rheumatoid Arthritis and

Related Disorders with Particular Reference to Retinopathy. N Engl J Med 273: 360-366 Sontheimer RD (2000) Questions answered and a $1 million question raised concerning lupus erythe-matosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloro-quine for skin disease really necessary. Arch Dermatol 136:1044-1049 Stein M, Bell MJ, Ang LC (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27: 2927-2931 Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27:2142-2145 Tett SE, McLachlan AJ, Cutler DJ, Day RO (1994) Pharmacokinetics and pharmacodynamis of hydrox-ychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of race-mate. Chirality 6:355-359

Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan TD (2000) The benefit of combining hydroxy-

chloroquine with quinacrine in the treatment of SLE patients. Lupus 9:92-95 Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cidicino A, Danoff D, Osterland CK, Yeadon C, Smith CD (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. Lupus 7:80-85 Urowitz M, Gladman D, Bruce I (2000) Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2:19-23

Versapuech J, Beylot-Barry M, Doutre MS, Beylot C (2000) Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 29:1596-1599 von Schmiedeberg S, Ronnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P (2000) Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythe-matosus. Hautarzt 51:82-85 Walker O, Ademowo OG (1996) A rapid, cost-effective liquid-chromatographic method for the determination for chloroquine and desethylchloroquine in biological fluids. Therap Drug Monitor 1:92-96

Wallace DJ (1989) The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin

Arthritis Rheum 18:282-296 Wallace DJ, Linker-Israeli M, Methger AL, Stecher VM (1993) The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2(Suppl 1):S13-S15 Wallace DJ (1996) The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5(Suppl 1):S59-S64 Wallace DJ (2000) Is there a role for quinacrine (Atabrine) in the new millennium? Lupus 9:81-82 Weber F, Schmuth M, Fritsch P, Sepp N (2001) Lymphocytic infiltration of the skin is a photosensitive variant of lupus erythematosus: evidence by phototesting. Br J Dermatol 144:292-296 Wechsler B, Le Thi Huong D, Piette JC (1999) Pregnancy and systemic lupus erythematosus. Ann Med

Interne (Paris) 150:408-418 Williams HJ, Egger MJ, Szinger JZ, Willkens RF, Kalunian KC, Clegg DO, Skosey JL, Brooks RH, Alarcon GS, Steen VD, Polisson RP, Ward JR (1994) Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 21:1457-1462 Wollheim FA, Hanson A, Laurell CB (1978) Chloroquine treatment in rheumatoid arthritis. Scand J Rheumatol 7:171-176

Zeidler GS (1995) Chloroquin (Resochin8) Synoptische Darstellung eines Pharmakons und seiner Indikation in der Medizin, speziell in der Dermatologie. In: Hautklinik. Düsseldorf: Heinrich-Heine University, Inaugural Dissertation Ziering CL, Rabinowith LG, Esterly NB (1993) Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 28:764-770

Was this article helpful?

0 0
Arthritis Joint Pain

Arthritis Joint Pain

Arthritis is a general term which is commonly associated with a number of painful conditions affecting the joints and bones. The term arthritis literally translates to joint inflammation.

Get My Free Ebook


Post a comment